Kisspeptin

Kisspeptin binds to its receptor KISS1R (also called GPR54) on GnRH neurons in the hypothalamus. This is the single most upstream regulatory gate of the hypothalamic-pituitary-gonadal axis. Receptor activation triggers GnRH pulse release, which drives pituitary LH and FSH secretion, which in turn stimulates gonadal sex hormone production (testosterone in men, estrogen/progesterone in women) and gametogenesis. Kisspeptin neurons also integrate environmental and metabolic signals (energy state, circadian rhythm, photoperiod, stress) to gate reproduction. The sexual desire and brain processing effects observed in HSDD trials are assumed to reflect both peripheral hormonal changes and direct central kisspeptin signaling, but the relative contributions are not established in humans.

Each claim carries a result tag next to its letter. The letter counts how many human randomized trials tested the claim, whether they worked or not; the tag says how they came out. Kisspeptin-54 and kisspeptin-10 are different lengths and are not interchangeable.

• One of the rare peptides with actual RCT data, but the trials are for IVF triggers and sexual dysfunction in clinical settings, not general optimization.
• The mechanism is real and well-characterized: upstream of the entire HPG axis, kisspeptin pulls the lever that starts testosterone and LH production.
• The catch is a big one: run it continuously and the LH response fades, as one small 2026 trial showed by day 5, and compounded kisspeptin-10 has been on FDA's do-not-compound list since 2023, with the advisory panel voting 0-11 against listing it in 2024.

Adverse events

Across a published human experience the Imperial College group puts above 1,000 people, adverse events have been mild and transient: injection site reactions (redness, swelling, tenderness), transient flushing, mild headache, nausea, and lightheadedness. No serious adverse events related to kisspeptin have been reported in any published clinical study. All trials were short-duration single-session or brief window administrations; this is not a long-term safety database.

Contraindications

Hormone-sensitive cancers (KISS1 has established cancer biology beyond reproduction; it was originally identified as a metastasis suppressor, and the cancer biology has no human safety characterization in wellness populations). Active pregnancy outside controlled medical setting. Hormone-dependent conditions. Anyone on GnRH agonists or antagonists (mechanistic conflict). KISS1R mutations (some individuals have variant receptor function).

Theoretical concerns

Receptor desensitization (KISS1R downregulates with sustained stimulation via beta-arrestin internalization) is real in humans with continuous exposure: in a small 2026 randomized study gonadotropins fell back to placebo levels by day 5 of a continuous infusion, while a daily 8-hour infusion kept LH raised for 12 days. Neither design tested a self-injected wellness dose, and none showed LH falling below baseline. Supraphysiologic or ill-timed dosing could disrupt GnRH pulsatility. Potential interference with fertility in men (excessive kisspeptin tone may paradoxically impair sperm function). No data on effects in women who are or could become pregnant outside of IVF contexts.

What nobody knows yet

No long-term safety data beyond short-term research dosing windows. No data on chronic daily use in healthy people. No data on interactions with TRT, GLP-1 agonists, or exogenous peptide stacks. No pharmacovigilance database for wellness use. Optimal isoform (KP-10 vs KP-54), dose, route, and cycling interval for any off-label purpose are entirely undefined.

What else could explain the result

Often used alongside TRT (which already supplies exogenous testosterone, making any 'kisspeptin-raised T' claim unattributable). Stacked with GH peptides like ipamorelin or sermorelin (confounds libido and body comp outcomes). Context of IVF trials includes exogenous gonadotropins. In HSDD trials, pre-existing psychological or relationship factors are not fully controlled. Online self-reports frequently combine kisspeptin with PT-141 (bremelanotide), making libido attribution impossible.

Is the vial what it says?

Cross-checked against the cited sources below. The grade reflects the absence of formal human safety and efficacy data. All cited PMIDs resolve. The first IVF live-birth trial was published in JCI in 2014 (PMID 25036713). FDA's PCAC voted 0 yes, 11 no in October 2024 against the 503A list. The HSDD evidence depends on a single institution, and the IVF use is investigational.

Half-life and storage

Half-life: KP-10 has a half-life of approximately 3.8-4.1 minutes in humans. KP-54 has a half-life of approximately 27.6 minutes. Both are rapidly degraded by circulating proteases, particularly at the N-terminus. Neither persists beyond roughly 30 minutes post-injection in blood.

Once mixed: Moderate sensitivity. Lyophilized powder should be reconstituted with bacteriostatic water (BAC water), not sterile saline (shorter shelf life). Avoid vigorous shaking. Store reconstituted peptide refrigerated (2-8C) and use within 28-30 days. KP-10 is particularly susceptible to N-terminal proteolysis and oxidation of the tryptophan residue; minimize freeze-thaw cycles.

What people report

Volume of reports: mixed. Reports exist but contradict each other.

Low-moderate. Kisspeptin has a small but growing wellness community presence, primarily in men pursuing natural testosterone optimization or libido enhancement. Volume is much lower than GH secretagogues or BPC-157.

Mixed. Users on TRT cannot attribute any benefit to kisspeptin specifically. Off-TRT reports describe modest libido improvement in some users and no effect in others. IVF and HSDD use cases map to real clinical data but are not wellness optimization contexts.

Low-moderate. Most self-reports come from people already on complex stacks. The clinical trial signal (IVF, HSDD) is real and peer-reviewed but does not map cleanly to the 'raise T, improve libido' wellness framing. Anecdote quality is poor relative to the actual research quality on this peptide.

• Anecdote: Some male users off TRT report noticeably increased morning erections and libido within a couple of weeks of self-injection, though attributability is low without pre/post labs.
• Anecdote: Users on TRT typically report no perceptible effect, consistent with the fact that the HPG axis is already suppressed and LH is not the rate-limiting step.
• Anecdote: A subset of users report flushing, headache, or mild nausea within 30 minutes of injection, consistent with the mild adverse events seen in clinical studies.
• Anecdote: Several forum reports describe initial benefit followed by loss of effect after a few weeks, which is mechanistically plausible given KISS1R desensitization data from research settings.

Reports are anecdote, not proof.

Can you tell if it is working?

First documented human use: 2003, when two independent research groups (de Roux et al. and Seminara et al.) identified loss-of-function KISS1R mutations causing hypogonadotropic hypogonadism in humans; first exogenous administration in humans was published around 2005 by Dhillo et al. at Imperial College London.

1. 1996KISS1 gene identified as a metastasis suppressor in malignant melanoma research; named after Hershey, Pennsylvania (home of Hershey Kisses chocolate), where the discovery was made.
2. 2003Two independent groups (de Roux in France, Seminara at Harvard) publish simultaneous findings that loss-of-function mutations in KISS1R cause hypogonadotropic hypogonadism, establishing kisspeptin as the gatekeeper of human puberty and reproduction.
3. 2014Jayasena, Abbara, Dhillo and colleagues at Imperial College London publish the first proof-of-concept human IVF trial using kisspeptin-54 as an oocyte maturation trigger, resulting in live births and no serious OHSS. Published in the Journal of Clinical Investigation (PMID 25036713). A related Lancet abstract (Abbara et al., DOI 10.1016/S0140-6736(14)60280-4) was published in the same year. Marks the transition from basic science to clinical application.
4. 2022-2023Back-to-back RCTs in JAMA Network Open (men 2023, women 2022) demonstrate kisspeptin modulates sexual brain processing in people with HSDD, generating mainstream press coverage and driving wellness-market interest. Both trials conducted at Imperial College London; independent replication is pending.
5. 2024October 29, 2024: FDA Pharmacy Compounding Advisory Committee (PCAC) voted 0-11 against placing kisspeptin-10 on the 503A Bulks List, the list of substances that compounding pharmacies may legally use. The use reviewed was treatment of secondary hypogonadism in men; the minutes record agreement that it should not be listed due to the lack of convincing safety and efficacy data. Kisspeptin-10 had been in FDA's Category 2 (compounding not permitted) since September 29, 2023 and was still there on FDA's list updated May 14, 2026. FDA meeting record: https://www.fda.gov/advisory-committees/advisory-committee-calendar/october-29-2024-meeting-pharmacy-compounding-advisory-committee-10292024

• Kisspeptin and its Current Clinical Status - A Systematic Review (Curr Med Chem 2025, PMID 38265397)(Systematic review of 33 clinical trial records; its trial-registry search ended in February 2023, so it predates the newest human studies.)
• Effects of Kisspeptin on Sexual Brain Processing and Penile Tumescence in Men With HSDD (PMC 2023, PMC9898824)(The RCT that generated most of the mainstream press. Double-blind crossover, n=32, published JAMA Network Open. Imperial College London; not independently replicated.)
• Kisspeptin-54 IVF Trigger Efficacy - Phase 2 Trial (PMC 2015, PMC4570165)(Strongest evidence in the kisspeptin literature. Phase 2 RCT with live birth outcomes; no moderate, severe or critical OHSS at any dose. Kisspeptin-54 remains investigational as an IVF trigger with no regulatory approval as of this profile.)
• Kisspeptin-54 IVF trigger, second-dose Phase 2 RCT (Hum Reprod 2017, PMID 28854728)(A second randomized phase 2 trial in the IVF trigger setting, which supports the A grade on the IVF claim.)
• The kisspeptin-GnRH pathway in human reproductive health and disease (PMC 2014, PMC4063702)(Foundational mechanism review covering the full HPG axis upstream control by kisspeptin; explains both the genuine biology and the limits of translation to wellness use.)
• FDA PCAC October 29, 2024 Meeting - Kisspeptin-10 503A Bulks Review (FDA.gov)(Official FDA record of the PCAC meeting at which kisspeptin-10 was voted 11-0 for exclusion from the 503A Bulks List. Cites insufficient safety data and unintended endocrine effect concerns.)
• Dhillo WS et al. Kisspeptin-54 stimulates the hypothalamic-pituitary gonadal axis in human males. J Clin Endocrinol Metab 2005;90:6609-15. PMID 16174713(dose table)
• George JT et al. Kisspeptin-10 is a potent stimulator of LH and increases pulse frequency in men. J Clin Endocrinol Metab 2011;96:E1228-36. PMID 21632807(dose table)
• Jayasena CN et al. Kisspeptin-54 triggers egg maturation in women undergoing in vitro fertilization. J Clin Invest 2014;124:3667-77. PMID 25036713(dose table)
• Abbara A et al. Efficacy of kisspeptin-54 to trigger oocyte maturation in women at high risk of OHSS during IVF therapy. J Clin Endocrinol Metab 2015;100:3322-31. PMID 26192876(dose table)
• Abbara A et al. A second dose of kisspeptin-54 improves oocyte maturation in women at high risk of ovarian hyperstimulation syndrome: a Phase 2 randomized controlled trial. Hum Reprod 2017;32:1915-24. PMID 28854728(dose table)
• Mills EG et al. Effects of kisspeptin on sexual brain processing and penile tumescence in men with hypoactive sexual desire disorder: a randomized clinical trial. JAMA Netw Open 2023;6:e2254313. PMID 36735255(dose table)
• Thurston L et al. Effects of kisspeptin administration in women with hypoactive sexual desire disorder: a randomized clinical trial. JAMA Netw Open 2022;5:e2236131. PMID 36287566(dose table)
• Intranasal kisspeptin administration rapidly stimulates gonadotropin release in humans. EBioMedicine 2025;115:105689. PMID 40215751(dose table)
• Kisspeptin administration stimulates reproductive hormones but does not affect anxiety in humans. J Clin Endocrinol Metab 2025;110:3133-41. PMID 40036336(dose table)
• Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men. Eur J Endocrinol 2026;195:206-16. PMID 42549827(dose table)